Clinical trials: Empagliflozin
Kidney Transplantation, Metabolic Disorder
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
Advances in patient selection, organ procurement and preservation, surgical technique, immunosuppression, and infection prevention have conferred significant decrease in rejection, infection, and subsequently improve…
- Conditions
- Kidney Transplantation, Metabolic Disorder, Metformin, Empagliflozin
- Trial name
- NCT05013112
- Testing
- SGLT2 inhibitor, Metformin
- Where
- China
- Volunteers
- 105 people
- Sponsor
- West China Hospital
Cardiovascular Diseases
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Purpose: The overall hypothesis of the study is that the benefits attained in the EMPA-OUTCOME were, at least in part, mediated by a glucose-independent mechanism.
- Trial name
- EMPA-TROPISM (NCT03485222)
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetes Mellitus, Coronary Disease
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.
- Trial name
- ELITE (NCT03208465)
- Testing
- Empagliflozin, Sitagliptin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of Empagliflozin and metformin compared to the administration of single tablets (Empagliflozin and metformin ) in Chinese subjects.
- Trial name
- NCT02102932
- Testing
- 5 mg empagliflozin/850 mg metformin FDC, 12.5 mg empagliflozin, 850 mg metformin
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV-1-infection, Coronary Microvascular Dysfunction
Improving Coronary Vascular Health in Women
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may…
- Conditions
- HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic Disease
- Trial name
- INFORM_2 (NCT06843902)
- Testing
- Health Education, Subspecialty clinic referral
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Kidney Disease
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
This study aims to investigate whether new glucose-lowering medications, such as SGLT2 inhibitors (e.g., Forxiga/Jardiance) and GLP-1 receptor agonists (e.g., Ozempic), can reduce NETosis in diabetic patients, thereby mitigating…
- Trial name
- NETs (NCT06821919)
- Where
- Israel
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Western Galilee Hospital-Nahariya
Heart Failure, Cardiomyopathy, Dilated
Therapy to Maintain Remission in Dilated Cardiomyopathy
One third of patients diagnosed with heart failure demonstrate left ventricular reverse remodelling and recovery of cardiac function following a period of medical therapy.
- Conditions
- Heart Failure, Cardiomyopathy, Dilated, Cardiomyopathies, Heart Diseases
- Trial name
- TRED-HF2 (NCT06091475)
- Testing
- Other
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Fatty Liver, Nonalcoholic
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Study question 1:Could SGLT2-I improve hepatic fibrosis, steatosis, and inflammatory markers in type 2 diabetic patients with Metabolic associated steatotic liver disease Question 2:Which drug of SGLT2-I group is more effective…
- Trial name
- NCT06117137
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Healthy Volunteers
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers
- Trial name
- NCT07102719
- Testing
- HD-P023, Teneligliptin and Empagliflozin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Heart Failure With Reduced Ejection Fraction, Heart Failure
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
This is a multicenter, randomized, open-label pilot study to evaluate whether stepwise withdrawal of two heart failure medications-angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitor…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
- Trial name
- STEP-DOWN HF (NCT07631156)
- Testing
- Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy
- Where
- 5 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Type 2 Diabetes
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings.
- Trial name
- NCT07003191
- Testing
- Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination)
- Where
- China
- Volunteers
- 2,600 people
- Sponsor
- Sun Yat-sen University
Chronic Kidney Disease
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or…
- Trial name
- NCT06926660
- Testing
- Vicadrostat, Empagliflozin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 492 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Diabetes Mellitus
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
Empagliflozin treatment in high cardiovascular risk patients has been shown to have a relatively rapid powerful capability in reducing cardiovascular mortality.
- Conditions
- Heart Failure, Diabetes Mellitus, Arrythmia
- Trial name
- ERA-HF (NCT03271879)
- Testing
- Empagliflozin at a dose of 10 mg/day
- Volunteers
- 128 people
- Sponsor
- Rambam Health Care Campus
Type 2 Diabetes Mellitus
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
The primary aim of this exploratory mechanistic study is to investigate the effects of Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients.
- Trial name
- NCT02401880
- Testing
- Linagliptin, Empagliflozin
- Where
- 2 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Diabetes Mellitus, Type 2
Regulatory Request NIS in Korea
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT03642717
- Testing
- JARDIANCE DUO®
- Where
- 20 sites in South Korea
- Volunteers
- 658 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Postprandial Hypoglycemia, Bariatric Surgery
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
The purpose of the study is to investigate whether hypoglycaemia observed after food intake in bariatric patients can be either influenced by an SGLT2 inhibitor, empagliflozin, or via inhibition of inflammation with an human…
- Conditions
- Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping Syndrome
- Trial name
- Hypo-BEAR (NCT03200782)
- Testing
- Empagliflozin, Anakinra
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- University Hospital, Basel, Switzerland
HFpEF, LVDD
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with [angiotensin receptor/neprilysin inhibitor [ARNI]…
- Conditions
- HFpEF, LVDD, Myocardial Fibrosis
- Trial name
- NCT06655480
- Testing
- [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Transplant; Failure, Heart, Cardiac Allograft Vasculopathy
Impact of SGLT2 Inhibitors in Heart Transplant Recipients
The goal of this clinical trial is to test if SGLT2 inhibitors could prevent or delay the development of Cardiac Allograft Vasculopathy (CAV) post-heart transplantation (TxC).
- Conditions
- Transplant; Failure, Heart, Cardiac Allograft Vasculopathy, Rejection Heart Transplant
- Trial name
- NCT06147271
- Testing
- SGLT2i
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Ceara